reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Endonovo Therapeutics, Inc.

ENDV · OTC

Not currently scored

This filer is no longer a domestic reporting company, so the score does not apply to it now. Its history is below.

—public float
2024-02-02delisted or deregistered

Score over time

01234202220232024202520262022-01-01 · score 42021-11-15 filed late (10-Q) · auditor2021-08-16 filed late (10-Q) · auditor2021-05-17 filed late (10-Q) · auditor2021-03-31 filed late (10-K) · auditor2022-04-01 · score 42022-03-31 filed late (10-K) · auditor2021-11-15 filed late (10-Q) · auditor2021-08-16 filed late (10-Q) · auditor2021-05-17 filed late (10-Q) · auditor2022-07-01 · score 42022-05-16 filed late (10-Q) · auditor2022-03-31 filed late (10-K) · auditor2021-11-15 filed late (10-Q) · auditor2021-08-16 filed late (10-Q) · auditor2022-10-01 · score 42022-08-15 filed late (10-Q) · auditor2022-05-16 filed late (10-Q) · auditor2022-03-31 filed late (10-K) · auditor2021-11-15 filed late (10-Q) · auditor2023-01-01 · score 42022-11-14 filed late (10-Q) · auditor2022-08-15 filed late (10-Q) · auditor2022-05-16 filed late (10-Q) · auditor2022-03-31 filed late (10-K) · auditor2023-04-01 · score 42023-03-31 filed late (10-K) · auditor2022-11-14 filed late (10-Q) · auditor2022-08-15 filed late (10-Q) · auditor2022-05-16 filed late (10-Q) · auditor2023-07-01 · score 42023-05-16 filed late (10-Q) · accounts not ready2023-03-31 filed late (10-K) · auditor2022-11-14 filed late (10-Q) · auditor2022-08-15 filed late (10-Q) · auditor2023-10-01 · score 42023-08-15 filed late (10-Q) · accounts not ready2023-05-16 filed late (10-Q) · accounts not ready2023-03-31 filed late (10-K) · auditor2022-11-14 filed late (10-Q) · auditor2024-01-01 · score 42023-11-15 filed late (10-Q) · accounts not ready2023-08-15 filed late (10-Q) · accounts not ready2023-05-16 filed late (10-Q) · accounts not ready2023-03-31 filed late (10-K) · auditor2024-04-01 · score 32023-11-15 filed late (10-Q) · accounts not ready2023-08-15 filed late (10-Q) · accounts not ready2023-05-16 filed late (10-Q) · accounts not ready2024-07-01 · score 22023-11-15 filed late (10-Q) · accounts not ready2023-08-15 filed late (10-Q) · accounts not ready2024-10-01 · score 12023-11-15 filed late (10-Q) · accounts not ready

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Endonovo Therapeutics, Inc. (the “Company”) is not in a position to file its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”) in a timely manner because the Company cannot complete the Form 10-Q without unreasonable effort or expense. As a result, the Company is still in the process of compiling the required information to complete the Quarterly Report. The Company does not expect to file its Quarterly Report on Form 10-Q prior to the fifth calendar day following the prescribed due date

NT 10-Q, filed 2023-11-15 · accounts not ready

What it filed

2023-11-15filed late (10-Q)accounts not ready SEC →

Endonovo Therapeutics, Inc. (the “Company”) is not in a position to file its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”) in a timely manner because the Company cannot complete the Form 10-Q without unreasonable effort or expense. As a result, the Company is still in the process of compiling the required information to complete the Quarterly Report. The Company does not expect to file its Quarterly Report on Form 10-Q prior to the fifth calendar day following the prescribed due date

2023-08-15filed late (10-Q)accounts not ready SEC →

Endonovo Therapeutics, Inc. (the “Company”) is not in a position to file its Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the “Form 10-Q”) in a timely manner because the Company cannot complete the Form 10-Q in a timely manner without unreasonable effort or expense. As a result, the Company is still in the process of compiling required information to complete the Quarterly Report. The Company intends to file its Quarterly Report on Form 10-Q no later than the fifth calendar day following the prescribed due date

2023-05-16filed late (10-Q)accounts not ready SEC →

Endonovo Therapeutics, Inc. (the “Company”) is not in a position to file its Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the “Form 10-Q”) in a timely manner because the Company cannot complete the Form 10-Q in a timely manner without unreasonable effort or expense. As a result, the Company is still in the process of compiling required information to complete the Quarterly Report. The Company intends to file its Quarterly Report on Form 10-Q no later than the fifth calendar day following the prescribed due date

2023-03-31filed late (10-K)auditor SEC →

Endonovo Therapeutics, Inc. (the “Company”) is not in a position to file its Annual Report on Form 10-K for the period ended December 31, 2022 (the “Form 10-K”) in a timely manner because the Company cannot complete the Form 10-K in a timely manner without unreasonable effort or expense. As a result, the Company is still in the process of compiling required information to complete the Annual Report and its independent registered public accounting firm requires additional time to complete its audit of the consolidated financial statements for the year ended December 31, 2022, to be incorporated in the Annual Report. The Company intends to file its Annual Report on Form 10-K no later than the fifteenth calendar day following the prescribed due date

2022-11-14filed late (10-Q)auditor SEC →

Endonovo Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Quarterly Report”) by the November 14, 2022, filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Quarterly Report. As a result, the Registrant is still in the process of compiling required information to complete the Quarterly Report and its independent registered public accounting firm requires additional time to complete its review of the financial statements for the quarter ended September 30, 2022, to be incorporated in the Quarterly Report. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing date

2022-08-15filed late (10-Q)auditor SEC →

Endonovo Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended June 30, 2022 (the “Quarterly Report”) by the August 15, 2022, filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Quarterly Report. As a result, the Registrant is still in the process of compiling required information to complete the Quarterly Report and its independent registered public accounting firm requires additional time to complete its review of the financial statements for the quarter ended June 30, 2022, to be incorporated in the Quarterly Report. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing date

2022-05-16filed late (10-Q)auditor SEC →

Endonovo Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended March 31, 2022 (the “Quarterly Report”) by the May 15, 2022, filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Quarterly Report. As a result, the Registrant is still in the process of compiling required information to complete the Quarterly Report and its independent registered public accounting firm requires additional time to complete its review of the financial statements for the quarter ended March 31, 2022, to be incorporated in the Quarterly Report. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing date

2022-03-31filed late (10-K)auditor SEC →

Endonovo Therapeutics, Inc. (the “Company”) is not in a position to file its Annual Report on Form 10-K for the period ended December 31, 2021 (the “Form 10-K”) in a timely manner because the Company cannot complete the Form 10-K in a timely manner without unreasonable effort or expense. As a result, the Company is still in the process of compiling required information to complete the Annual Report and its independent registered public accounting firm requires additional time to complete its audit of the financial statements for the year ended December 31, 2021 to be incorporated in the Annual Report. The Company intends to file its Annual Report on Form 10-K no later than the fifteenth calendar day following the prescribed due date

2021-11-15filed late (10-Q)auditor SEC →

Endonovo Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended September 30, 2021 (the “Quarterly Report”) by the November 15, 2021, filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Quarterly Report. As a result, the Registrant is still in the process of compiling required information to complete the Quarterly Report and its independent registered public accounting firm requires additional time to complete its review of the financial statements for the quarter ended September 30, 2021, to be incorporated in the Quarterly Report. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing date

2021-08-16filed late (10-Q)auditor SEC →

Endonovo Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended June 30, 2021 (the “Quarterly Report”) by the August 16, 2021, filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Quarterly Report. As a result, the Registrant is still in the process of compiling required information to complete the Quarterly Report and its independent registered public accounting firm requires additional time to complete its review of the financial statements for the quarter ended June 30, 2021, to be incorporated in the Quarterly Report. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing date

2021-05-17filed late (10-Q)auditor SEC →

Endonovo Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the “Quarterly Report”) by the May 17, 2021 filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Quarterly Report. As a result, the Registrant is still in the process of compiling required information to complete the Quarterly Report and its independent registered public accounting firm requires additional time to complete its review of the financial statements for the quarter ended March 31, 2021 to be incorporated in the Quarterly Report. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing date. Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number

2021-03-31filed late (10-K)auditor SEC →

Endonovo Therapeutics, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the period ended December 31, 2019 (the “Annual Report”) by the March 31, 2021 filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Annual Report. As a result, the Registrant is still in the process of compiling required information to complete the Annual Report and its independent registered public accounting firm requires additional time to complete its audit of the financial statements for the year ended December 31, 2020 to be incorporated in the Annual Report. The Registrant anticipates that it will file the Annual Report no later than the fifteenth calendar day following the prescribed filing date. Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com